In a retrospective study of patients with malignant melanoma in multiple melanoma centers around the world, patients with BRAFV600 mutations with elevated LDH levels who received anti-PD-1 antibody and anti-CTLA-4 antibody had longer PFS and OS than patients treated with first-line targeted therapy or a single ICI. The gene discussed is PDCD1; the disease is melanoma.